Document is current
Any future updates will be listed below
-
Authors
Gilbert, Rodney D.
Al-Dakkak, Imad
Boothe, Clare
Cobb, Timothy E.
Gale, Daniel P.
Griffin, Sian
Marks, Stephen D.
Scully, Marie
Shenoy, Mohan
Waters, Aoife
Sheerin, Neil S.
-
Funding
Funding for this research was provided by:
This study was sponsored by Alexion, AstraZeneca Rare Disease.
- License Information
-
More Information
Article History
Received: 7 April 2025
Accepted: 7 July 2025
First Online: 5 August 2025
Declarations
:
: The aHUS Registry is approved through the Research Ethics Committee (REC) North East; Newcastle and North Tyneside 2, chaired by Professor Barry Hirst. The REC approvals are provided to the individual participating sites in the Registry. The Registry is conducted in accordance with International Conference on Harmonisation Good Clinical Practice Guidelines and the Declaration of Helsinki. Written informed consent was provided by patients or their parents or guardians, as deemed applicable by institutional review boards or the ethics committee.
: Not Applicable.
: RDG has received several honoraria from Alexion for lectures on aHUS and serving on advisory boards. SDM and AW have no disclosures relating to this manuscript. MSc has received honoraria and a research grant from Alexion. DPG, SG, MSh and NSS have received honoraria from Alexion. CB and TEC are current employees of Alexion, AstraZeneca Rare Disease. IAD, at the time of writing and reviewing, was an employee of AstraZeneca Rare Disease.
